When:
Time: 3:30am PDT, 6:30am EDT, 11:30am BST, 12:30pm CEST
Duration: 330 minutes
Natural language processing is a powerful technology that is being applied in new and innovative ways across healthcare and life science.
Join our in-person seminar series to hear about the advances in NLP and machine learning techniques being applied within healthcare, pharma, and government organizations. Learn about new applications for leveraging NLP to unlock key insights from unstructured text to improve patient outcome, safety assessment, brand awareness, and more.
The seminar will focus on topics such as precision medicine, risk adjustment, population health as well as generating high-quality data and insights for drug discovery, safety, regulatory and medical affairs teams.
During this one day seminar, there will be customers’ use case presentations using IQVIA NLP, product updates and IQVIA overview along with networking opportunities with your peers and IQVIA NLP Experts, knowledge sharing and hands-on learning.
Topics covered:
The final agenda will be available in the weeks ahead but use cases will cover:
- Providers & Health Systems, Payers & Insurance Companies
- Pharma discovery, safety, regulatory, and medical affairs
Who should attend:
- Current customers – we would love to say hi in person and show you our latest solutions
- Researchers, scientists, product teams, clinicians
- Data scientist, technical architect, executive in innovation, analytics quality or data role working with lots of unstructured data
- Anyone struggling to get the information you need from volumes of unstructured record and texts
This event we will be a good opportunity to learn about Innovative NLP Solutions and how others use NLP to solve their data challenges.
Quantitative social media listening in pharmaceutical research by Raul Rodriguez-Esteban, Senior Principal Scientist at Roche Pharmaceutical
Social media listening (SML) has the potential to help in many stages of the drug development process in the quest for patient-centric therapies that are fit-for-purpose and meaningful to patients. To fulfill this potential, however, it requires the leveraging of quantitative approaches and analytical methods that draw from developments in NLP and real-world data (RWD) analysis applied to the real-world text (RWT) of social media. These approaches fall under the umbrella of quantitative SML (QSML), which distinguishes itself from the qualitative methods that have been commonly used in the past. In this talk, I will describe what QSML is, why it is used and how it can support drug development, as well as ethical and legal considerations.
IQVIA Ontologies: comprehensive resources to connect data and enable interoperability and advanced analytics by Andrea Splendiani, Principal for Ontologies and Metadata at IQVIA
Ontologies are information resources that capture the definitions and relations between vocabularies, codes and classifications across different disciplines and languages. They underpin data and metadata standardization and are key both to connect and transform data into unified views, and to support different data centric approaches in data management (e.g.: FAIR data, Knowledge Graphs, Data Mesh).
In IQVIA we integrate healthcare data at a unique scale and therefore we have developed a wide range of data assets, technologies, and expertise pertaining ontologies and their application.
We believe that such capabilities developed to support our operations can benefit other organizations on a journey to leverage their data to innovate healthcare. In this talk we present IQVIA ontologies resources and what they can uniquely contribute.
Partnering with health systems to improve patient outcomes and product up-take through Quality Improvement programs by John Rigg, AI for Healthcare & MedTech, Global Head, Real-World Solutions at IQVIA
Life science companies are increasingly partnering with health systems to deliver patient innovative Quality Improvement programs. These initiatives have tremendous potential to bring benefits to providers, patients and pharma a-like, improving patient outcomes and product up-take. But these partnerships are often complex and there are many hurdles to navigate to achieve large-scale roll-out and success.
This presentation will illustrate what is meant by patient Quality Improvement programs, focusing on the exciting, rapidly growing use of Electronic Health Records (EHR) to target patients and evaluate program performance. Key challenges will be discussed, both at the macro-level and the project-level, covering technical as well as legal considerations. Finally, the presentation will illustrate key themes through case studies.
Innovating with AI: digital transformation for safety and regulatory affairs by Jane Reed, Director NLP Safety & Regulatory at IQVIA
The pharmaceutical industry is one of the world’s most heavily regulated industries, and the traditional document-centric approach poses challenges in terms of efficiency, cost and value. The ever-increasing volume of safety records and relevant regulatory data mean companies need tools and solutions to assist with safety and regulatory processes. Many companies are looking to innovative new technologies to transform document-driven processes to data-driven ones. In this session, we will discuss the potential that innovative NLP can bring, for digital transformation, automation, and human-in-the-loop augmented intelligence, presenting use cases from the FDA and top pharma.
Three ways NLP brings value to Medical Affairs, Real-World & Commercial teams by Hywel Evans, Director NLP for Medical Affairs & Commercialization at IQVIA
There is a huge amount of valuable text and document-based information available to medical and commercial teams, but it is often a challenge to work with. From notes captured by field teams that capture the unmet needs of physicians, patient perspective online, to the latest scientific literature and congress abstracts, this data can inform content development, medical and commercial strategy, competitive insights and more. Join us to hear about three examples of applied AI and NLP to unlock these invaluable data sources.
Accelerating Drug Development with NLP by Constantinos Kateatis, Associate Director NLP R&D at IQVIA
The growing document volume and varied data sources in drug development is a constant challenge. Natural language processing (NLP) technologies are key to efficiently keep up with the latest information. Generate insights 10-100x faster by combining new innovative large language models (LLMs) with established methods for a range of drug development tasks, including target identification, target prioritization, clinical trial design, and more.
Speakers
Raul Rodriguez-Esteban
Senior Principal Scientist at Roche PharmaceuticalRaul Rodriguez-Esteban
Raul Rodriguez-Esteban is Senior Principal Scientist at Roche Pharmaceuticals in Basel, Switzerland, where he works on natural language processing, machine learning and real-world data applied to pharmaceutical R&D. Previously, he worked in pharmaceutical R&D at Boehringer Ingelheim and Pfizer. He completed his PhD in machine learning applied to text mining at the laboratory of Andrey Rzhetsky at Columbia University. He was a winner of the Bio-IT World Innovative Practices Award in 2020, is member of the Executive Committee of the International Society for Biocuration (ISB) and is editorial board member of the journal BMC Digital Health.
Andrea Splendiani
Principal for Ontologies and Metadata at IQVIAAndrea Splendiani
Andrea Splendiani, PhD, is Principal for Ontologies and Metadata at IQVIA. He is a Computer Scientist and Bioinformatician by training and he has been widely active in the ontology, semantic and FAIR communities in both academia and pharma. He’s focused on connecting and curating data to enhance their value.
Jane Reed
Director, NLP, Safety & RegulatoryJane Reed
Jane Reed is Director of NLP at Linguamatics, an IQVIA company. She is responsible for leading the strategic vision for Linguamatics product portfolio and business development for the pharma and biotech market, with a focus on safety and regulatory. Jane has 20+ years’ experience in vendor companies supplying data products, data integration and analysis, and consultancy to pharma and biotech—with roles at Instem, BioWisdom, Incyte, and Hexagen. Before moving into the life science industry, Jane worked in academia with post-docs in genetics and genomics. Jane holds a MA from Cambridge University and a PhD from Birmingham University.
Hywel Evans
Director, NLP for Medical Affairs & CommercializationHywel Evans
Hywel Evans leads the development, application and delivery of IQVIA’s (formerly Linguamatics) NLP offerings within Medical Affairs and Commercial Pharma teams and has been with IQVIA for over 6 years. He also leads the NLP Insight Hub offering, which transforms and integrates information from a wide range of structured and unstructured data sources into a single convenient platform. Hywel was previously a Principal leading Real World Technology & Analytics for the APAC region based in Singapore, leading a team of data scientists and consultants in the design & delivery of analytics solutions, and the development of real-world data assets and collaborations. Hywel has consulting and technology experience across life sciences, healthcare, financial services and consumer industries. He has expertise in building analytics and data teams, delivering data driven strategies, designing and executing behavioral insights and stakeholder engagement initiatives. Prior to joining IQVIA, Hywel was a consultant at Booz&Co and EY. He holds a Master’s degree (MEng) in Engineering from the University of Cambridge.
Constantinos Katevatis
Associate Director, R&D NLPConstantinos Katevatis
Constantinos Katevatis is Associate Director, R&D NLP at Linguamatics, an IQVIA company. He is responsible for developing the strategic vision of Linguamatics’ product portfolio and business development for R&D and clinical operations in the pharma and biotech industries. Constantinos has experience and expertise in NLP-centric data extraction and data management across the pharma product life cycle. Before joining the life science industry, Constantinos completed a doctorate on DNA-based medical devices.
Paul Milligan
Director, Product StrategyPaul Milligan
Paul started at the company as an Application Specialist in 2005. In his role, he is responsible for product management, marketing, and strategy guidance of I2E, an award-winning agile, high performance enterprise text mining software. Paul also has responsibility for the I2E Web Services API, to allow integration of text mining capabilities into large-scale workflows. He has worked on many customer projects, including analysis of historical pre-clinical records, large-scale extraction of information from patents and semantic annotation for enterprise search. Paul has a PhD from University of Cambridge in computational drug design where his work involved developing algorithms to optimize combinatorial libraries for protein-ligand interactions. Before joining Linguamatics, Paul worked in the Cambridge biotech sector creating bioinformatics and chemoinformatics tools for processing of diverse large databases, including PDB, compound registries and PubMed.
Andrew Hinton
Senior NLP Application Scientist at IQVIAAndrew Hinton
Andrew Hinton is a Senior Application Scientist who provides NLP solutions for extracting information from unstructured data such as scientific literatures, patents and real world clinical notes. Andrew is an expert in providing NLP solutions and support across the customer journey, including consulting services, training, and client engagement. Andrew has 11+ years of experience in NLP centric data extraction and analytics
John Rigg
AI for Healthcare & MedTech, Global Head, Real-World Solutions at IQVIAJohn Rigg
John is the Global Head of IQVIA’s AI for Healthcare & MedTech group. The team focuses on supporting healthcare providers in improving healthcare delivery and closing care gaps. The team has enjoyed widespread recognition for its AI expertise, developing well over 100 AI solutions covering most major disease areas and many rare diseases, many of which have been published in scientific peer-review journals. John is also leading IQVIA’s global initiative to develop provider-integrated capability to enable the large-scale deployment of AI algorithms for population-based screening diagnostics, risk stratification and similar applications.
John has over twenty years experience developing AI solutions in life sciences, financial services and academia. He is frequently invited to give thought leadership presentations in industry and academia. John received his PhD in Economics from Cambridge University and has held post-doctoral research positions at the London School of Economics and the University of Essex.
